Bio View

Bio View Days Sales Outstanding

The Days Sales Outstanding (DSO) of Bio View (BIOV.TA) as of Oct 28, 2026 is 66.33. In the previous year, Days Sales Outstanding (DSO) was 77.77 — a change of -14.72% (lower).

Days Sales Outstanding

66.33

YoY

-14.72%

Last updated:

Days Sales Outstanding (DSO) of Bio View is 2024 66.33 . Days Sales Outstanding (DSO) of Bio View was 2023 77.77 . It decreases by -14.72% lower compared to the previous year.

The Bio View Days Sales Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Sales Outstanding
Date
Days Sales Outstanding
Jan 1, 2017
61.92 ILS
Jan 1, 2018
44.22 ILS
Jan 1, 2019
43.86 ILS
Jan 1, 2020
45.32 ILS
Jan 1, 2021
52.85 ILS
Jan 1, 2022
66.19 ILS
Jan 1, 2023
77.77 ILS
Jan 1, 2024
66.33 ILS
The Bio View Days Sales Outstanding history
YEARDays Sales OutstandingYoY
66.33-14.72%
77.77+17.50%
66.19+25.24%
52.85+16.62%
45.32+3.31%
43.86-0.82%
44.22-28.57%
61.92+21.46%
50.97+59.12%
32.04-47.60%
61.13—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio View Stock analysis

What does Bio View do? BioView Ltd. generates revenue through the sale and servicing of its Duet automated cell diagnostic system, designed for use in cytology, cytogenetic, hematology, and pathology laboratories. The Duet system enables automated detection, classification, analysis, and counting of cells, offering unique capabilities in analyzing both cell morphology and genetic content simultaneously. Additional products include the ALLEGRO workstation for automated scanning of FISH probes without Brightfield scanning and the ACCORD workstation for semi-automated imaging of FISH in breast cancer (Her-2/Neu) analysis and FISH on tissue. These systems target medical professionals in cancer diagnosis, minimal-residual disease monitoring, prenatal and postnatal cytogenetic analyses, sperm cell studies, and rare-cell detection. The company's primary customers are laboratories specializing in cytology, cytogenetics, hematology, and pathology, including those focused on cancer diagnostics and genetic analysis. These institutions purchase the Duet system for routine diagnostic workflows and the ALLEGRO and ACCORD workstations for specialized applications such as FISH analysis in breast cancer and genetic studies. BioView Ltd. also provides ongoing servicing and support for its systems, contributing to recurring revenue streams. BioView Ltd. markets its products under the brand names Duet, ALLEGRO, and ACCORD, with the Duet system serving as the core offering for general cell analysis. The ALLEGRO and ACCORD workstations cater to niche applications in FISH-based diagnostics, particularly in oncology and genetic testing. The company's revenue is derived from direct sales of these systems to healthcare facilities and laboratories, with no mention of third-party partnerships or additional revenue streams beyond product sales and servicing. Bio View is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio View stock

Days Sales Outstanding (DSO) of Bio View is 66.33 in 2024.

Days Sales Outstanding (DSO) of Bio View changed from 77.77 to 66.33, representing a -14.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Sales Outstanding (DSO) Bio View since 2006 – with annual values, charts, and detailed analysis.

DSO measures the average number of days it takes to collect payment after a sale. Lower DSO indicates faster cash collection.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Sales Outstanding (DSO)'s Bio View with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Sales Outstanding (DSO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Sales Outstanding (DSO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Bio View

All Key Metrics — Bio View